Findings of Impaired Hearing in Patients With Nonfluent/Agrammatic Variant Primary Progressive Aphasia

RECOMMENDED

Multiple Sclerosis

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial

Mult Scler.

Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Pei J, Musch B, Giovannoni G

doi: 10.1177/1352458518808189.

Aging and Cognitive FunctionsAlzheimer’s Disease

Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia

JAMA Neurol.

Santos-Santos MA, Rabinovici GD, Iaccarino L, Ayakta N, Tammewar G, Lobach I, Henry ML, Hubbard I, Mandelli ML, Spinelli E, Miller ZA, Pressman PS, O'Neil JP, Ghosh P, Lazaris A, Meyer M, Watson C, Yoon SJ, Rosen HJ, Grinberg L, Seeley WW, Miller BL, Jagust WJ, Gorno-Tempini ML

doi: 10.1001/

Multiple Sclerosis

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

Ann Neurol.

Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L

doi: 10.1002/ana.25313.

Aging and Cognitive FunctionsAnxiety and DepressionDementia

Depressive Symptoms are Associated with Progression to Dementia in Patients with Amyloid-Positive Mild Cognitive Impairment

J Alzheimers Dis.

Moon B, Kim S, Park YH, Lim JS, Youn YC, Kim SY, Jang JW, Alzheimer’s Disease Neuroimaging Initiative

doi: 10.3233/JAD-170225.

Aging and Cognitive FunctionsAlzheimer’s Disease

Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment

JAMA Neurol.

Wolk AD, Sadowsky C, Safirstein B, Rinne JO, Duara J, Perry R, Agronin M, Gamez J, Shi J, Ivanoiu A, Minthon L, Walker Z, Hasselbalch S, Holmes C, Sabbagh M, Albert M, Fleisher A, Loughlin P, Triau E, Frey K, Høgh P, Bozoki A, Bullock R, Salmon E, Farrar G, Buckley CJ, Zanette M, Sherwin PF, Cherubini A, Inglis F

doi: 10.1001/

Multiple Sclerosis

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

Brain.

Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M

doi: 10.1093/brain/awx250.

Multiple Sclerosis

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis

JAMA Neurol.

Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, Scotti B, Zecca C, Gobbi C, Kappos L, Derfuss T

doi: 10.1001/jamaneurol.

Multiple Sclerosis

Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

Eur J Neurol.

Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Menoyo JLS, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group

doi: 10.1111/ene.13824.

Aging and Cognitive FunctionsBipolar Disorder

Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study

Lancet Psychiatry.

Yatham LN, Mackala S, Basivireddy J, Ahn S, Walji N, Hu C, Lam RW, Torres IJ

doi: 10.1016/

Related content

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial

Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

Depressive Symptoms are Associated with Progression to Dementia in Patients with Amyloid-Positive Mild Cognitive Impairment

Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis

Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study